Merus (NASDAQ:MRUS - Get Free Report) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Tuesday.
A number of other brokerages also recently issued reports on MRUS. William Blair reissued an "outperform" rating on shares of Merus in a research report on Monday, April 22nd. Stifel Nicolaus upped their price objective on shares of Merus from $40.00 to $65.00 and gave the stock a "buy" rating in a report on Thursday, February 29th. Needham & Company LLC restated a "buy" rating and issued a $66.00 price target on shares of Merus in a research note on Monday. HC Wainwright restated a "buy" rating and set a $65.00 price objective on shares of Merus in a research note on Thursday, May 9th. Finally, BMO Capital Markets upped their price target on Merus from $49.00 to $58.00 and gave the company an "outperform" rating in a report on Thursday, February 29th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, Merus currently has a consensus rating of "Moderate Buy" and an average target price of $56.33.
View Our Latest Stock Analysis on MRUS
Merus Price Performance
MRUS stock traded down $1.08 during midday trading on Tuesday, reaching $44.77. The company had a trading volume of 589,606 shares, compared to its average volume of 609,291. Merus has a 1 year low of $19.81 and a 1 year high of $52.03. The company has a market capitalization of $2.63 billion, a P/E ratio of -16.16 and a beta of 1.10. The firm has a 50-day moving average price of $44.64 and a 200-day moving average price of $36.14.
Merus (NASDAQ:MRUS - Get Free Report) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.24. The company had revenue of $7.89 million for the quarter, compared to analysts' expectations of $8.94 million. Merus had a negative net margin of 390.36% and a negative return on equity of 44.13%. On average, equities analysts predict that Merus will post -3.31 EPS for the current year.
Institutional Trading of Merus
A number of large investors have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC grew its holdings in shares of Merus by 37.7% in the fourth quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 343 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Merus by 142.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company's stock worth $35,000 after buying an additional 867 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Merus by 64.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company's stock valued at $58,000 after buying an additional 828 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Merus in the 1st quarter valued at about $72,000. Finally, SG Americas Securities LLC purchased a new position in Merus in the first quarter worth about $108,000. Institutional investors own 96.14% of the company's stock.
Merus Company Profile
(
Get Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
